IDH1-VAC (IDH1 R132H Peptide Vaccine)
NOA-16
German Cancer Research Center · Phase 1 · Completed · Enrollment 39
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| IDH1-vac | newly diagnosed IDH1 R132H astrocytoma | not stated in source | Single arm | n/r | vaccine-induced immune response: 93.3%, 28 of 30 evaluable3-year PFS rate: 63% |